Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Open accessThe DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Abstract
There are many factors that can influence the pharmacokinetics (PK) of a mAb or Fc-fusion molecule with the primary determinant being FcRn-mediated recycling. Through Fab or Fc engineering, IgG-FcRn interaction can be used to generate a variety of therapeutic antibodies with significantly enhanced half-life or ability to remove unwanted antigen from circulation. Glycosylation of a mAb or Fc-fusion protein can have a significant impact on the PK of these molecules. mAb charge can be important and variants with pI values of 1-2 unit difference are likely to impact PK with lower pI values being favorable for a longer half-life. Most mAbs display target mediated drug disposition (TMDD), which can have significant consequences on the study designs of preclinical and clinical studies. The PK of mAb can also be influenced by anti-drug antibody (ADA) response and off-target binding, which require careful consideration during the discovery stage. mAbs are primarily absorbed through the lymphatics via convection and can be conveniently administered by the subcutaneous (sc) route in large doses/volumes with co-formulation of hyaluronidase. The human PK of a mAb can be reasonably estimated using cynomolgus monkey data and allometric scaling methods.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346 · cited 5×
“The binding area of IgG to FcRn is located between the CH2 and CH3 domain, distinctly different from the FcγR binding domain that is located between the CH1 and CH2 domain (Kim et al., 1994a; Roopenian & Akilesh, 2007).”
BackgroundInfluentialCarbohydrate-Specific Receptors of the Liver
Ashwell, G., & Harford, J. (1982) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.51.070182.002531 · Cited by 1,914
The Impact of Glycosylation on the Biological Function and Structure of Human Immunoglobulins
Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M., & Dwek, R. A. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141702 · Cited by 1,307
The therapeutic monoclonal antibody market
Ecker, D. M., Jones, S. D., & Levine, H. L. (2015) · mAbs · doi:10.4161/19420862.2015.989042 · Cited by 1,286
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978
Antibody Pharmacokinetics and Pharmacodynamics
Lobo, E. D., Hansen, R. J., & Balthasar, J. P. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20178 · Cited by 909
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829 · cited 2×
“Glycosylation patterns can impact both PK and PD significantly (Arnold et al., 2007; Jefferis, 2009a).”
BackgroundBartelds, G. M. (2011) · JAMA · doi:10.1001/jama.2011.406 · Cited by 782
Harding, F. A., Stickler, M. M., Razo, J., & DuBridge, R. (2010) · mAbs · doi:10.4161/mabs.2.3.11641 · Cited by 737
An Fc receptor structurally related to MHC class I antigens
Simister, N. E., & Mostov, K. E. (1989) · Nature · doi:10.1038/337184a0 · Cited by 729 · cited 1×
“The “hypothesized” Brambell receptor, later called neonatal Fc receptor (FcRn), was cloned in 1989 (Simister & Mostov, 1989).”
BackgroundAntibody Multispecificity Mediated by Conformational Diversity
James, L. C., Roversi, P., & Tawfik, D. S. (2003) · Science · doi:10.1126/science.1079731 · Cited by 719
General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition
Mager, D. E., & Jusko, W. J. (2001) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1023/a:1014414520282 · Cited by 605
Tao, M. H., & Morrison, S. L. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.8.2595 · Cited by 530
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
Dirks, N. L., & Meibohm, B. (2010) · Clinical Pharmacokinetics · doi:10.2165/11535960-000000000-00000 · Cited by 500
Goetze, A. M., Liu, Y. D., Zhang, Z., Shah, B., Lee, E., Bondarenko, P. V., & Flynn, G. C. (2011) · Glycobiology · doi:10.1093/glycob/cwr027 · Cited by 467 · cited 3×
“Glycosylated mAbs with terminal high mannose glycans have been shown to exhibit fast clearance from the blood (Goetze et al., 2011; Kanda et al., 2007; Liu et al., 2011; Wright & Morrison, 1994; Wright et al., 2000; Yu et al., 2012).”
BackgroundTHE TRANSMISSION OF IMMUNITY FROM MOTHER TO YOUNG AND THE CATABOLISM OF IMMUNOGLOBULINS
Brambell, F. W. R. (1966) · The Lancet · doi:10.1016/s0140-6736(66)92190-8 · Cited by 463
A Theoretical Model of γ-Globulin Catabolism
BRAMBELL, F. W. R., HEMMINGS, W. A., & MORRIS, I. G. (1964) · Nature · doi:10.1038/2031352a0 · Cited by 449
Biological significance of carbohydrate chains on monoclonal antibodies.
Nose, M., & Wigzell, H. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.21.6632 · Cited by 437
Liu, L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24444 · Cited by 428 · cited 6×
“The impacts of glycosylation on the PK and PD of mAbs and Fc-fusion proteins have been reviewed extensively elsewhere (Liu, 2015) and will be only briefly discussed here.”
BackgroundResultInfluentialKhawli, L. A., Goswami, S., Hutchinson, R., Kwong, Z. W., Yang, J., Wang, X., Yao, Z., Sreedhara, A., Cano, T., Tesar, D. B., et al. (2010) · mAbs · doi:10.4161/mabs.2.6.13333 · Cited by 419
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels
Vaccaro, C., Zhou, J., Ober, R. J., & Ward, E. S. (2005) · Nature Biotechnology · doi:10.1038/nbt1143 · Cited by 407 · cited 1×
“…for FcRn at pH 6 with little or no binding to FcRn at neutral pH can lead to 2–4-fold longer terminal half-lives in cynomolgus and rhesus monkeys (Yeung et al., 2009, 2010; Vaccaro et al., 2005; Olafsen, 2012; Hinton et al., 2004,2006; Deng et al., 2010; Datta-Mannan et al., 2007a, b, 2012a, b).”
BackgroundEffects of Charge on Antibody Tissue Distribution and Pharmacokinetics
Boswell, C. A., Tesar, D. B., Mukhyala, K., Theil, F.-P., Fielder, P. J., & Khawli, L. A. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100261d · Cited by 398
Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration
Richter, W. F., Bhansali, S. G., & Morris, M. E. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9367-0 · Cited by 377 · cited 6×
“The highly porous lymphatic system allows the transport of macromolecules (>20 kDa MW) through the convective flow of the interstitial fluids (Richter et al., 2012; Richter & Jacobsen, 2014).”
BackgroundInfluentialWu, H., Pfarr, D. S., Johnson, S., Brewah, Y. A., Woods, R. M., Patel, N. K., White, W. I., Young, J. F., & Kiener, P. A. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.02.024 · Cited by 373
Kanda, Y., Yamada, T., Mori, K., Okazaki, A., Inoue, M., Kitajima-Miyama, K., Kuni-Kamochi, R., Nakano, R., Yano, K., Kakita, S., et al. (2007) · Glycobiology · doi:10.1093/glycob/cwl057 · Cited by 372
Robbie, G. J., Criste, R., Dall'Acqua, W. F., Jensen, K., Patel, N. K., Losonsky, G. A., & Griffin, M. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01285-13 · Cited by 366
Rudnick, S. I., Lou, J., Shaller, C. C., Tang, Y., Klein-Szanto, A. J. P., Weiner, L. M., Marks, J. D., & Adams, G. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2277 · Cited by 365 · cited 3×
“High affinity was found to produce low tumor accumulation (Rudnick et al., 2011) (Fig.”
BackgroundInfluentialA modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.
Fujimori, K., Covell, D. G., Fletcher, J. E., & Weinstein, J. N. (1990) · PubMed · Cited by 356
Igawa, T., Ishii, S., Tachibana, T., Maeda, A., Higuchi, Y., Shimaoka, S., Moriyama, C., Watanabe, T., Takubo, R., Doi, Y., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1691 · Cited by 353
Sampei, Z., Igawa, T., Soeda, T., Okuyama-Nishida, Y., Moriyama, C., Wakabayashi, T., Tanaka, E., Muto, A., Kojima, T., Kitazawa, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057479 · Cited by 336
Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy
Chirmule, N., Jawa, V., & Meibohm, B. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9340-y · Cited by 335
Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action
Jefferis, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.04.007 · Cited by 330
Alt, N., Zhang, T. Y., Motchnik, P., Taticek, R., Quarmby, V., Schlothauer, T., Beck, H., Emrich, T., & Harris, R. J. (2016) · Biologicals · doi:10.1016/j.biologicals.2016.06.005 · Cited by 294 · cited 3×
“This general relationship has also been validated more recently in humans with the M252Y/S254T/T256E (YTE) set of mutations constructed on the Fc of a mAb against respiratory syncytial virus (RSV) with half-life increases from around 20 days to more than 60 days (Robbie et al., 2013).”
BackgroundDeng, R., Iyer, S., Theil, F.-P., Mortensen, D. L., Fielder, P. J., & Prabhu, S. (2011) · mAbs · doi:10.4161/mabs.3.1.13799 · Cited by 285 · cited 2×
“Human concentration–time profiles were also reasonably predicted from the cynomolgus monkey data using species-invariant time method with a fixed exponent of 0.85 for CL and 1.0 for volume of distribution (Deng et al., 2011).”
BackgroundMethodInfluentialAn Engineered Human IgG1 Antibody with Longer Serum Half-Life
Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T., Keller, S., & Tsurushita, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.346 · Cited by 282
A recombinant human enzyme for enhanced interstitial transport of therapeutics
Bookbinder, L. H., Hofer, A., Haller, M. F., Zepeda, M. L., Keller, G.-A., Lim, J. E., Edgington, T. S., Shepard, H. M., Patton, J. S., & Frost, G. I. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.05.027 · Cited by 282
Polyreactivity of antibody molecules
Notkins, A. L. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.02.004 · Cited by 281
Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates
Hinton, P. R., Johlfs, M. G., Xiong, J. M., Hanestad, K., Ong, K. C., Bullock, C., Keller, S., Tang, M. T., Tso, J. Y., Vásquez, M., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300470200 · Cited by 273
Approximations of the Target-Mediated Drug Disposition Model and Identifiability of Model Parameters
Gibiansky, L., Gibiansky, E., Kakkar, T., & Ma, P. (2008) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-008-9102-8 · Cited by 272 · cited 3×
“For this reason, many analyses use empirical approaches for building models that require less information about the drug target interaction, receptor numbers, and turnover rates (Dua et al., 2015; Gibiansky et al., 2008; Grimm, 2009; Mager, 2006).”
BackgroundMethodReduced elimination of IgG antibodies by engineering the variable region
Igawa, T., Tsunoda, H., Tachibana, T., Maeda, A., Mimoto, F., Moriyama, C., Nanami, M., Sekimori, Y., Nabuchi, Y., Aso, Y., et al. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq009 · Cited by 265 · cited 6×
“Therefore, more sophisticated mechanistic models are needed for the TMDD analysis.”
BackgroundMethodInfluentialShah, D. K., & Betts, A. M. (2013) · mAbs · doi:10.4161/mabs.23684 · Cited by 262
Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies
Wang, W., Vlasak, J., Li, Y., Pristatsky, P., Fang, Y., Pittman, T., Roman, J., Wang, Y., Prueksaritanont, T., & Ionescu, R. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2010.12.009 · Cited by 257
A strategy for risk mitigation of antibodies with fast clearance
Hötzel, I., Theil, F.-P., Bernstein, L. J., Prabhu, S., Deng, R., Quintana, L., Lutman, J., Sibia, R., Chan, P., Bumbaca, D., et al. (2012) · mAbs · doi:10.4161/mabs.22189 · Cited by 245
Fasanmade, A. A., Adedokun, O. J., Olson, A., Strauss, R., & Davis, H. M. (2010) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp48297 · Cited by 245
Zahnd, C., Kawe, M., Stumpp, M. T., de Pasquale, C., Tamaskovic, R., Nagy-Davidescu, G., Dreier, B., Schibli, R., Binz, H. K., Waibel, R., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2724 · Cited by 245
Target-mediated drug disposition and dynamics
Mager, D. E. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.041 · Cited by 244
Yeung, Y. A., Leabman, M. K., Marvin, J. S., Qiu, J., Adams, C. W., Lien, S., Starovasnik, M. A., & Lowman, H. B. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804182 · Cited by 237
Therapeutic antibodies: Market considerations, disease targets and bioprocessing
Elvin, J. G., Couston, R. G., & van der Walle, C. F. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.12.039 · Cited by 237
Subcutaneous Absorption of Biotherapeutics: Knowns and Unknowns
Richter, W. F., & Jacobsen, B. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.059238 · Cited by 235
Impact of methionine oxidation on the binding of human IgG1 to FcRn and Fcγ receptors
Bertolotti-Ciarlet, A., Wang, W., Lownes, R., Pristatsky, P., Fang, Y., McKelvey, T., Li, Y., Li, Y., Drummond, J., Prueksaritanont, T., et al. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.02.002 · Cited by 235
Interaction sites on human IgG-Fc for FcγR: current models
Jefferis, R., & Lund, J. (2002) · Immunology Letters · doi:10.1016/s0165-2478(02)00019-6 · Cited by 220
FcRn: the MHC class I-related receptor that is more than an IgG transporter
Ghetie, V., & Ward, E. S. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01172-9 · Cited by 216
Mould, D. R., & Sweeney, K. (2007) · PubMed · Cited by 208
Junghans, R. P. (1997) · Immunologic Research · doi:10.1007/bf02786322 · Cited by 205
Yu, M., Brown, D., Reed, C., Chung, S., Lutman, J., Stefanich, E., Wong, A., Stephan, J.-P., & Bayer, R. (2012) · mAbs · doi:10.4161/mabs.20737 · Cited by 203 · cited 2×
“They introduced a negatively charged amino acid (Tyr30glu) near the patch and observed a significant improvement in PK (Sampei et al., 2013).”
BackgroundMethionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn
Pan, H., Chen, K., Chu, L., Kinderman, F., Apostol, I., & Huang, G. (2009) · Protein Science · doi:10.1002/pro.45 · Cited by 203
Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics
Schoch, A., Kettenberger, H., Mundigl, O., Winter, G., Engert, J., Heinrich, J., & Emrich, T. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408766112 · Cited by 202 · cited 3×
“More recently, Gao et al. showed with mutagenesis analyses that either M252 or M428 oxidation alone significantly impaired Fc–FcRn binding.”
BackgroundResultFixed Dosing Versus Body Size—Based Dosing of Monoclonal Antibodies in Adult Clinical Trials
Wang, D. D., Zhang, S., Zhao, H., Men, A. Y., & Parivar, K. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009337512 · Cited by 192 · cited 3×
“The dosing strategy in later stages of clinical development could then be determined based on combined knowledge of the body weight effect on pharmacokinetics, safety, and efficacy observed in the early clinical trials (Bai et al., 2012; Wang et al., 2009).”
BackgroundMethodWright, A., & Morrison, S. L. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.3.1087 · Cited by 192
Practical Theoretic Guidance for the Design of Tumor-Targeting Agents
Wittrup, K. D., Thurber, G. M., Schmidt, M. M., & Rhoden, J. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-396962-0.00010-0 · Cited by 171
Datta-Mannan, A., Witcher, D. R., Tang, Y., Watkins, J., & Wroblewski, V. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607161200 · Cited by 170
Wang, W., Lu, P., Fang, Y., Hamuro, L., Pittman, T., Carr, B., Hochman, J., & Prueksaritanont, T. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.039453 · Cited by 166
A Guide to Rational Dosing of Monoclonal Antibodies
Bai, S., Jorga, K., Xin, Y., Jin, D., Zheng, Y., Damico-Beyer, L. A., Gupta, M., Tang, M., Allison, D. E., Lu, D., et al. (2012) · Clinical Pharmacokinetics · doi:10.2165/11596370-000000000-00000 · Cited by 165
A Tutorial on Target-Mediated Drug Disposition (TMDD) Models
Dua, P., Hawkins, E., & van der Graaf, P. (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.41 · Cited by 162 · cited 2×
“For this reason, many analyses use empirical approaches for building models that require less information about the drug target interaction, receptor numbers, and turnover rates (Dua et al., 2015; Gibiansky et al., 2008; Grimm, 2009; Mager, 2006).”
MethodDong, J. Q., Salinger, D. H., Endres, C. J., Gibbs, J. P., Hsu, C.-P., Stouch, B. J., Hurh, E., & Gibbs, M. A. (2011) · Clinical Pharmacokinetics · doi:10.2165/11537430-000000000-00000 · Cited by 156
Muller, P. Y., Milton, M., Lloyd, P. M., Sims, J., & Brennan, F. R. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.013 · Cited by 152
Zheng, Y., Tesar, D. B., Benincosa, L., Birnböck, H., Boswell, C. A., Bumbaca, D., Cowan, K. J., Danilenko, D. M., Daugherty, A. L., Fielder, P. J., et al. (2012) · mAbs · doi:10.4161/mabs.4.2.19387 · Cited by 149
Huang, Q., & Riviere, J. E. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.934671 · Cited by 149
Mullamitha, S. A., Ton, N. C., Parker, G. J. M., Jackson, A., Julyan, P. J., Roberts, C., Buonaccorsi, G. A., Watson, Y., Davies, K., Cheung, S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2779 · Cited by 146
Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look
Ling, J., Zhou, H., Jiao, Q., & Davis, H. M. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009337134 · Cited by 144 · cited 1×
“…of mAbs with non-target related elimination pathways or doses above the target saturation levels in humans can be reasonably predicted using data from cynomolgus monkeys with an allometric exponent of ∼0.85 (Deng et al., 2011; Dong et al., 2011; Ling et al., 2009; Wang & Prueksaritanont, 2010).”
BackgroundInfluentialKim, J., Tsen, M., Ghetie, V., & Ward, E. S. (1994) · European Journal of Immunology · doi:10.1002/eji.1830241025 · Cited by 142
Datta‐Mannan, A., Witcher, D. R., Tang, Y., Watkins, J. D., Jiang, W., & Wroblewski, V. J. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.011734 · Cited by 140
Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
Shpilberg, O., & Jackisch, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.371 · Cited by 138 · cited 3×
“…to administer mAb’s for oncology indications which typically require much larger doses and volumes (Jackisch et al., 2014; Salar et al., 2014; Shpilberg & Jackisch, 2013). rHuPH20, a recombinant hyaluronidase temporarily cleaving hyaluronan fibers in the interstitial tissue, and thereby…”
BackgroundMethodInfluentialJones, A. J. S., Papac, D. I., Chin, E. H., Keck, R., Baughman, S. A., Lin, Y. S., Kneer, J., & Battersby, J. E. (2007) · Glycobiology · doi:10.1093/glycob/cwm017 · Cited by 137
Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting
Danilov, S. M., Gavrilyuk, V. D., Franke, F. E., Pauls, K., Harshaw, D. W., McDonald, T. D., Miletich, D. J., & Muzykantov, V. R. (2001) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.2001.280.6.l1335 · Cited by 135
Immunogenicity of mAbs in non-human primates during nonclinical safety assessment
van Meer, P. J. K., Kooijman, M., Brinks, V., Gispen-de Wied, C. C., Silva-Lima, B., Moors, E. H. M., & Schellekens, H. (2013) · mAbs · doi:10.4161/mabs.25234 · Cited by 132
Wynne, C., Harvey, V., Schwabe, C., Waaka, D., McIntyre, C., & Bittner, B. (2013) · The Journal of Clinical Pharmacology · doi:10.1177/0091270012436560 · Cited by 128
Amelioration of Experimental Autoimmune Myasthenia Gravis in Rats by Neonatal FcR Blockade
Liu, L., Garcia, A. M., Santoro, H., Zhang, Y., McDonnell, K., Dumont, J., & Bitonti, A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.8.5390 · Cited by 122
Self-citationLi, B., Tesar, D., Boswell, C. A., Cahaya, H. S., Wong, A., Zhang, J., Meng, Y. G., Eigenbrot, C., Pantua, H., Diao, J., et al. (2014) · mAbs · doi:10.4161/mabs.29809 · Cited by 122
Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody Therapeutics
Bumbaca, D., Boswell, C. A., Fielder, P. J., & Khawli, L. A. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9369-y · Cited by 119
Deng, R., Loyet, K. M., Lien, S., Iyer, S., DeForge, L. E., Theil, F., Lowman, H. B., Fielder, P. J., & Prabhu, S. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.031310 · Cited by 116
The effect of Fc glycan forms on human IgG2 antibody clearance in humans
Chen, X., Liu, Y. D., & Flynn, G. C. (2008) · Glycobiology · doi:10.1093/glycob/cwn120 · Cited by 115
Gao, X., Ji, J. A., Veeravalli, K., Wang, Y. J., Zhang, T., Mcgreevy, W., Zheng, K., Kelley, R. F., Laird, M. W., Liu, J., et al. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24136 · Cited by 112
Wright, A., Sato, Y., Okada, T., Chang, K. H., Endo, T., & Morrison, S. L. (2000) · Glycobiology · doi:10.1093/glycob/10.12.1347 · Cited by 111
Sachs, U. J. H., Socher, I., Braeunlich, C. G., Kroll, H., Bein, G., & Santoso, S. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02408.x · Cited by 110
Ng, C. M., Stefanich, E. G., Anand, B. S., Fielder, P. J., & Vaickus, L. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-8814-3 · Cited by 109
Bumbaca, D., Wong, A., Drake, E., Reyes II, A. E., Lin, B. C., Stephan, J.-P., Desnoyers, L., Shen, B.-Q., & Dennis, M. S. (2011) · mAbs · doi:10.4161/mabs.3.4.15786 · Cited by 105
Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited
Wang, W., & Prueksaritanont, T. (2010) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.708 · Cited by 105
Engineered Monoclonal Antibody with Novel Antigen-Sweeping Activity In Vivo
Igawa, T., Maeda, A., Haraya, K., Tachibana, T., Iwayanagi, Y., Mimoto, F., Higuchi, Y., Ishii, S., Tamba, S., Hironiwa, N., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063236 · Cited by 105
Igawa, T., Haraya, K., & Hattori, K. (2016) · Immunological Reviews · doi:10.1111/imr.12392 · Cited by 101
Salar, A., Avivi, I., Bittner, B., Bouabdallah, R., Brewster, M., Catalani, O., Follows, G., Haynes, A., Hourcade-Potelleret, F., Janikova, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.2631 · Cited by 98
Neonatal Fc Receptor Blockade by Fc Engineering Ameliorates Arthritis in a Murine Model
Patel, D. A., Puig-Canto, A., Challa, D. K., Montoyo, H. P., Ober, R. J., & Ward, E. S. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003780 · Cited by 93
Subcutaneous Administration of Monoclonal Antibodies in Oncology
Jackisch, C., Müller, V., Maintz, C., Hell, S., & Ataseven, B. (2014) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0034-1368173 · Cited by 90
Kelly, R. L., Sun, T., Jain, T., Caffry, I., Yu, Y., Cao, Y., Lynaugh, H., Brown, M., Vásquez, M., Wittrup, K. D., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1043503 · Cited by 90
Wang, W., Chen, N., Shen, X., Cunningham, P. K., Fauty, S. E., Michel, K. B., Wang, B., Hong, X., Adreani, C. M., Nunes, C. N., et al. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.043604 · Cited by 86
Self-citationBumbaca Yadav, D., Sharma, V. K., Boswell, C. A., Hotzel, I., Tesar, D., Shang, Y., Ying, Y., Fischer, S. K., Grogan, J. L., Chiang, E. Y., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.692434 · Cited by 82
Ternant, D., Arnoult, C., Pugnière, M., Dhommée, C., Drocourt, D., Pérouzel, É., Passot, C., Baroukh, N., Mulleman, D., Tiraby, G., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501780 · Cited by 82
Oitate, M., Masubuchi, N., Ito, T., Yabe, Y., Karibe, T., Aoki, T., Murayama, N., Kurihara, A., Okudaira, N., & Izumi, T. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-11-rg-011 · Cited by 81
Liu, L., Stadheim, A., Hamuro, L., Pittman, T. J., Wang, W., Zha, D., Hochman, J. H., & Prueksaritanont, T. (2011) · Biologicals · doi:10.1016/j.biologicals.2011.06.002 · Cited by 81
Self-citationLee, H. J., & Pardridge, W. M. (2003) · Bioconjugate Chemistry · doi:10.1021/bc0256648 · Cited by 79
A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
Yeung, Y. A., Wu, X., Reyes, A. E., Vernes, J.-M., Lien, S., Lowe, J., Maia, M., Forrest, W. F., Meng, Y. G., Damico, L. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4580 · Cited by 78
Fc Receptors as Adaptive Immunoreceptors
Daëron, M. (2014) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-07911-0_7 · Cited by 73
Kobayashi, H., Le, N., Kim, I. S., Kim, M. K., Pie, J.-E., Drumm, D., Paik, D. S., Waldmann, T. A., Paik, C. H., & Carrasquillo, J. A. (1999) · PubMed · Cited by 73
Keck, R. G., Nayak, N., Lerner, L. E., Raju, S., Ma, S., Schreitmueller, T., Chamow, S., Moorhouse, K., Kotts, C. E., & Jones, A. J. S. (2007) · Biologicals · doi:10.1016/j.biologicals.2007.05.004 · Cited by 72
A Novel Strategy To Reduce the Immunogenicity of Biological Therapies
Somerfield, J., Hill-Cawthorne, G. A., Lin, A., Zandi, M. S., McCarthy, C., Jones, J., Willcox, M., Shaw, D. M., Thompson, S. A. J., Compston, A., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000422 · Cited by 72
Elimination of the Immunogenicity of Therapeutic Antibodies
Gilliland, L. K., Walsh, L. A., Frewin, M. R., Wise, M. P., Tone, M., Hale, G., Kioussis, D., & Waldmann, H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.6.3663 · Cited by 70
Wang, J., Iyer, S., Fielder, P. J., Davis, J. D., & Deng, R. (2016) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1952 · Cited by 69 · cited 3×
“However, PBPK models are complex, mathematically difficult to construct, poorly suited to population analyses, and often limited because of a lack of tissue concentration data, parameter availability, or parameter identifiability (Shah & Betts, 2013; Wang et al., 2016).”
BackgroundMethodKIM, J. ‐., TSEN, M. ‐., GHETIE, V., & WARD, E. S. (1994) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.1994.tb03488.x · Cited by 69
Liu, L., Gomathinayagam, S., Hamuro, L., Prueksaritanont, T., Wang, W., Stadheim, T. A., & Hamilton, S. R. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0921-3 · Cited by 69
Self-citationDatta‐Mannan, A., Chow, C.-K., Dickinson, C. D., Driver, D. A., Lu, J., Witcher, D. R., & Wroblewski, V. J. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.045864 · Cited by 66
Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis
Challa, D. K., Bussmeyer, U., Khan, T., Montoyo, H. P., Bansal, P., Ober, R. J., & Ward, E. S. (2013) · mAbs · doi:10.4161/mabs.25439 · Cited by 60
Olafsen, T., Kenanova, V. E., & Wu, A. M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.322 · Cited by 56
Mi, Y., Lin, A., Fiete, D., Steirer, L. M., & Baenziger, J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.544973 · Cited by 53
Grimm, H. P. (2009) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-009-9129-5 · Cited by 53
Datta-Mannan, A., Witcher, D. R., Lu, J., & Wroblewski, V. J. (2012) · mAbs · doi:10.4161/mabs.4.2.19364 · Cited by 53
An FDA oncology analysis of immune activating products and first-in-human dose selection
Saber, H., Gudi, R., Manning, M. L., Wearne, E., & Leighton, J. K. (2016) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2016.10.002 · Cited by 53
Vugmeyster, Y., Szklut, P., Wensel, D. L., Ross, J. E., Xu, X., Awwad, M., Gill, D. S., Tchistiakov, L., & Warner, G. L. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0405-x · Cited by 52
Bittner, B., Richter, W., Hourcade-Potelleret, F., McIntyre, C., Herting, F., Zepeda, M., & Schmidt, J. (2012) · Arzneimittelforschung · doi:10.1055/s-0032-1321831 · Cited by 51
Datta‐Mannan, A., Croy, J. E., Schirtzinger, L., Torgerson, S., Breyer, M. D., & Wroblewski, V. J. (2016) · mAbs · doi:10.1080/19420862.2016.1178435 · Cited by 51
Richter, W. F., Gallati, H., & Schiller, C.-D. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14878-7 · Cited by 50
Pennica, D., Lam, V. T., Weber, R. F., Kohr, W. J., Basa, L. J., Spellman, M. W., Ashkenazi, A., Shire, S. J., & Goeddel, D. V. (1993) · Biochemistry · doi:10.1021/bi00063a027 · Cited by 46
Bittner, B., Richter, W., Hourcade-Potelleret, F., McIntyre, C., Herting, F., Zepeda, M., & Schmidt, J. (2013) · Drug Research · doi:10.1055/s-0033-1357211 · Cited by 38
Mao, C.-P., Brovarney, M. R., Dabbagh, K., Birnböck, H. F., Richter, W. F., & Del Nagro, C. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080533 · Cited by 37
Brenner, M. C., Krzyżański, W., Chou, J., Signore, P. E., Fung, C. K., Guzman, D., Li, D., Zhang, W., Olsen, D. R., Nguyen, V.-T. L., et al. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1918-0 · Cited by 33
Application of FcRn Binding Assays to Guide mAb Development
Datta‐Mannan, A., & Wroblewski, V. J. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.059089 · Cited by 32
Use of Fc-Engineered Antibodies as Clearing Agents to Increase Contrast During PET
Swiercz, R., Chiguru, S., Tahmasbi, A., Ramezani, S., Hao, G., Challa, D. K., Lewis, M. A., Kulkarni, P. V., Sun, X., Ober, R. J., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.136481 · Cited by 31
Off-target activity of TNF-α inhibitors characterized by protein biochips
Feyen, O., Lueking, A., Kowald, A., Stephan, C., Meyer, H. E., Göbel, U., & Niehues, T. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-1938-7 · Cited by 30
Fc Engineering: Serum Half-Life Modulation Through FcRn Binding
Olafsen, T. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-974-7_31 · Cited by 28
Luu, K. T., Kraynov, E. A., Kuang, B., Vicini, P., & Zhong, W.-Z. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9464-8 · Cited by 26
Evidence for an Asialoglycoprotein Receptor on Nonparenchymal Cells for O-Linked Glycoproteins
Stefanich, E. G., Song, R., Danilenko, D. M., Lim, A. M., Song, A., Iyer, S., & Fielder, P. J. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.142232 · Cited by 26
Kairemo, K., Lappalainen, A. K., Kääpä, E., Laitinen, O., Hyytinen, T., Karonen, S.-L., & Grönblad, M. (2001) · PubMed · Cited by 26
Clarke, S. J., Smith, J., Gebbie, C., Sweeney, C. J., & Olszewski, N. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3025 · Cited by 26
Glatt, D. M., Beckford-Vera, D., Parrott, M. C., Luft, J. C., Benhabbour, S. R., & Mumper, R. J. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00063 · Cited by 23
Abuqayyas, L., Zhang, X., & Balthasar, J. P. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.01.001 · Cited by 18
Lueking, A., Beator, J., Patz, E., Müllner, S., Méhes, G., & Amersdorfer, P. (2008) · BioTechniques · doi:10.2144/000112898 · Cited by 16
Cited by
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Considerations for the Design of Antibody-Based Therapeutics
Goulet, D. R., & Atkins, W. M. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 302
Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
Mahalingaiah, P. K., Ciurlionis, R., Durbin, K. R., Yeager, R. L., Philip, B. K., Bawa, B., Mantena, S. R., Enright, B. P., Liguori, M. J., & Van Vleet, T. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.008 · Cited by 286
Structure, heterogeneity and developability assessment of therapeutic antibodies
Xu, Y., Wang, D., Mason, B., Rossomando, T., Li, N., Liu, D., Cheung, J. K., Xu, W., Raghava, S., Katiyar, A., et al. (2019) · mAbs · doi:10.1080/19420862.2018.1553476 · Cited by 264
Wada, R., Matsui, M., & Kawasaki, N. (2019) · mAbs · doi:10.1080/19420862.2018.1551044 · Cited by 186
“This process is important in pharmacokinetics (PK) as a key part of regulating serum persistence.(16) FcRn is expressed in several organs and tissues.”
Background
Metadata
- Authors
- Liu, L.
- Venue
- Protein & Cell
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-04-19
- Volume
- 9
- Issue
- 1
- Pages
- 15-32
- ISSN
- 1674-800X (ISSN-L)
- 1674-8018
- OpenAlex
- W2606721249
- Cited by
- 390
- References
- 136
- FWCI
- 18.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.